Show simple item record

dc.contributor.authorFoo, Cher Ying
dc.contributor.authorFu, Richard Z; email: richard.fu@manchester.ac.uk
dc.date.accessioned2021-09-17T00:40:35Z
dc.date.available2021-09-17T00:40:35Z
dc.date.issued2021-07-21
dc.date.submitted2021-03-13
dc.identifierpubmed: 34474881
dc.identifierpii: S0928-4931(21)00469-0
dc.identifierdoi: 10.1016/j.msec.2021.112330
dc.identifier.citationMaterials science & engineering. C, Materials for biological applications, volume 128, page 112330
dc.identifier.urihttp://hdl.handle.net/10034/625874
dc.descriptionFrom PubMed via Jisc Publications Router
dc.descriptionHistory: received 2021-03-13, revised 2021-07-15, accepted 2021-07-18
dc.descriptionPublication status: ppublish
dc.description.abstractGlioblastoma multiforme (GBM) is one of the most malignant types of central nervous system tumours. Despite advances in treatment modalities, it remains largely incurable with an extremely poor prognosis. Treatment of GBM is associated with several difficulties such as the risk of damaging healthy brain tissues during surgery, drug resistance and inadequate drug delivery across the blood brain barrier. The new nanomaterial graphene, has recently attracted great attention due to its unique physico-chemical characteristics, good biocompatibility, specific targeting and small size. Starting from simple drug delivery systems, the application of graphene-based nanomaterials has been extended to a versatile platform of multiple therapeutic modalities, including immunotherapy, gene therapy, photothermal therapy and photodynamic therapy. Graphene-based materials can also be engineered to integrate multiple functions into a single platform for combination therapy for enhanced anticancer activity and reduced side effects. This review aims to discuss the state-of-the-art applications of graphene-based materials in GBM diagnosis and therapy. In addition, future challenges and prospects regarding this promising field are discussed, which may pave the way towards improving the safety and efficacy of graphene-based therapeutics. [Abstract copyright: Copyright © 2021 Elsevier B.V. All rights reserved.]
dc.languageeng
dc.sourceeissn: 1873-0191
dc.subjectNanomedicine
dc.subjectGlioblastoma
dc.subjectNanostructures
dc.subjectGraphite - therapeutic use
dc.subjectDiagnosis
dc.subjectDrug Delivery Systems
dc.subjectTheranostics
dc.subjectPhotochemotherapy
dc.subjectGraphene
dc.subjectBrain Neoplasms - drug therapy
dc.subjectHumans
dc.subjectCancer therapy
dc.subjectGlioblastoma - drug therapy
dc.titleUnravelling the potential of graphene in glioblastoma therapy.
dc.typearticle
dc.date.updated2021-09-17T00:40:35Z
dc.date.accepted2021-07-18


This item appears in the following Collection(s)

Show simple item record